Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Kumar on Navigating CAR T-Cell Therapy–Related Toxicities in MCL

August 13th 2021

Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.

Loncastuximab Tesirine and Ibrutinib Combination Shows Promise in R/R DLBCL and MCL

August 11th 2021

The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.

Dr. Park on Selecting Among Available CAR T-Cell Therapies in MCL

August 5th 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Dr. Kumar on the Clinical Implications of the AIM Study in Mantle Cell Lymphoma

August 4th 2021

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma.

Dr. Kumar on Patient Considerations for Treatment in Relapsed/Refractory MCL

August 3rd 2021

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

Dr. Phillips on the Future of CAR T-Cell Therapy in MCL

August 2nd 2021

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

Dr. Smith on the Patient Population of the ECOG-ACRIN E1411 Trial in MCL

July 26th 2021

Mitchell R. Smith, MD, PhD, discusses the patient population of the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Zanubrutinib Approved in Canada for MCL

July 26th 2021

Health Canada has approved the BTK inhibitor zanubrutinib for use in the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 therapy.

Venetoclax Plus Lenalidomide/Rituximab Elicits High Response Rates in Newly Diagnosed MCL

July 22nd 2021

The addition of venetoclax to lenalidomide and rituximab resulted in a high response rate and encouraging minimal residual disease undetectability in patients with newly diagnosed mantle cell lymphoma—even in those with high-risk features.

Addition of Bortezomib to Bendamustine/Rituximab Induction Therapy Does Not Significantly Improve PFS in MCL

July 21st 2021

Mitchell R. Smith, MD, PhD, discusses the results of the ECOG-ACRIN E1411 trial examining BR-based induction treatment in patients with mantle cell lymphoma and next steps for research.

Dr. Smith on the Rationale of the ECOG-ACRIN E1411 Trial in MCL

July 16th 2021

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Updates in the Treatment of Mantle Cell Lymphoma

July 16th 2021

This article discusses the current treatment landscape and therapeutic strategies for mantle cell lymphoma, the role of Bruton tyrosine kinase inhibitor therapies in MCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL

July 15th 2021

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Dr. Shah on Efforts to Combat Resistance to BTK Inhibitors in MCL

July 7th 2021

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

Dr. Phillips on the Next Steps With Venetoclax/Lenalidomide/Rituximab in MCL

July 7th 2021

Tycel Jovelle Phillips, MD, discusses the next steps in evaluating the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

FDA Grants Breakthrough Therapy Designation to Orelabrutinib for Relapsed/Refractory MCL

June 28th 2021

The FDA has granted a breakthrough therapy designation orelabrutinib for the treatment of patients with relapsed/refractory mantle cell lymphoma.

SOX11 Inhibitors Demonstrate Early Activity in MCL Models

June 24th 2021

Three first-in-class, SOX11 small molecule inhibitors demonstrated on-target antitumor activity in mantle cell lymphoma cell lines and in patient-derived ibrutinib-resistant models ex vivo.

Dr. Martin on the Findings of a Real-World Analysis of Outcomes in MCL

June 23rd 2021

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.

Discrepancies Between Real-World Patterns of Care and Recommendations Based on Clinical Trials Exist in MCL

June 23rd 2021

Peter Martin, MD, discusses discrepancies in real-world patterns of care for patients with MCL and what can be done to overcome them.

Loncastuximab Tesirine Continues to Impress in Relapsed/Refractory DLBCL and MCL

June 23rd 2021

Loncastuximab tesirine-lpyl continued to demonstrate promising antitumor activity with an acceptable toxicity profile when used in the treatment of select patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma.